Tower Wealth Partners Inc. Purchases Shares of 2,863 AstraZeneca PLC (NASDAQ:AZN)

Tower Wealth Partners Inc. acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,863 shares of the company’s stock, valued at approximately $223,000.

Several other institutional investors have also recently modified their holdings of the stock. McClarren Financial Advisors Inc. increased its position in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca during the 2nd quarter worth about $26,000. Pathway Financial Advisers LLC acquired a new position in AstraZeneca in the 1st quarter valued at about $29,000. RFP Financial Group LLC lifted its holdings in AstraZeneca by 56.3% in the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after purchasing an additional 178 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Up 0.4 %

Shares of AZN opened at $71.42 on Friday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company’s fifty day moving average is $79.17 and its two-hundred day moving average is $78.60. The firm has a market cap of $221.44 billion, a PE ratio of 34.50, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.

Analysts Set New Price Targets

Several brokerages recently issued reports on AZN. TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.